FAIRMOUNT FUNDS MANAGEMENT LLC
Q2 2024 Form 13-F
WEST CONSHOHOCKEN, PENNSYLVANIA
CIK 0001802528
· CRD 284844
· SEC-registered investment adviser
$885.1M Reported Value Total
FAIRMOUNT FUNDS MANAGEMENT LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $2,276,508,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $6.1B gross asset value
Hedge Fund: $5.7B · Private Equity Fund: $342.0M
Source: Form ADV filed 2026-08-07
Reported value
$885.1M
Quarter over quarter
-8.1%
Holdings
13
Top-10 concentration
94.3%
Key People
Form ADV owners & control persons
Peter Evan Harwin
MANAGING MEMBER
Tomas Kiselak
MANAGING MEMBER
Emily Florence Curtiss
GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $885.1M |
| Positions | 13 |
| Change in reported value | -3.5% |
| New positions | 2 |
| Exited positions | 4 |
| Position turnover | 35.3% |
| Top-10 concentration | 94.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
12 | $1.6B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
12 | $1.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
17 | $771.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
15 | $644.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
17 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $885.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
15 | $917.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
16 | $946.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
20 | $831.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $709.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
16 | $581.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
16 | $630.4M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
26 | $568.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
27 | $436.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
22 | $422.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
20 | $303.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 13 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | AXSM AXSOME THERAPEUTICS INC | $190.0M | 21.46% |
| 2 | NUVL NUVALENT INC | $146.0M | 16.5% |
| 3 | SYRE SPYRE THERAPEUTICS INC | $94.5M | 10.67% |
| 4 | APGE APOGEE THERAPEUTICS INC | $80.6M | 9.11% |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | $74.8M | 8.46% |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | $71.5M | 8.08% |
| 7 | KNSA KINIKSA PHARMACEUTICALS INTL | $59.8M | 6.76% |
| 8 | COGT COGENT BIOSCIENCES INC | $52.5M | 5.93% |
| 9 | ATXS ASTRIA THERAPEUTICS INC | $32.3M | 3.65% |
| 10 | PTGX PROTAGONIST THERAPEUTICS INC | $32.3M | 3.65% |
| 11 | VRDN VIRIDIAN THERAPEUTICS INC | $24.0M | 2.71% |
| 12 | BCYC BICYCLE THERAPEUTICS PLC | $21.6M | 2.44% |
| 13 | TERN TERNS PHARMACEUTICALS INC | $5.1M | 0.58% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.